Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of cardiovascular death or hospitalization for heart failure than those who received placebo.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine Jg. 383; H. 15; S. 1413 - 1424
Hauptverfasser: Packer, Milton, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Pocock, Stuart J, Carson, Peter, Januzzi, James, Verma, Subodh, Tsutsui, Hiroyuki, Brueckmann, Martina, Jamal, Waheed, Kimura, Karen, Schnee, Janet, Zeller, Cordula, Cotton, Daniel, Bocchi, Edimar, Böhm, Michael, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Janssens, Stefan, Zhang, Jian, Gonzalez Juanatey, Jose R, Kaul, Sanjay, Brunner-La Rocca, Hans-Peter, Merkely, Bela, Nicholls, Stephen J, Perrone, Sergio, Pina, Ileana, Ponikowski, Piotr, Sattar, Naveed, Senni, Michele, Seronde, Marie-France, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Wanner, Christoph, Zannad, Faiez
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Massachusetts Medical Society 08.10.2020
Schlagworte:
Aged
Antidiabetics
Benzhydryl Compounds - adverse effects
Benzhydryl Compounds - therapeutic use
Cardiology and cardiovascular system
Cardiovascular diseases
Cardiovascular Diseases - mortality
Cardiovascular Diseases - prevention & control
Congestive heart failure
Death
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 2 - complications
Disease Progression
Double-Blind Method
Drug dosages
Ejection fraction
Female
Genital tract
Glomerular filtration rate
Glomerular Filtration Rate - drug effects
Glucosides - adverse effects
Glucosides - therapeutic use
Heart failure
Heart Failure - complications
Heart Failure - drug therapy
Heart Failure - physiopathology
Hospitalization
Hospitalization - statistics & numerical data
Human health and pathology
Humans
Kidney diseases
Life Sciences
Male
Middle Aged
Peptides
Proportional Hazards Models
Quality of life
Renal Insufficiency, Chronic - complications
Sodium-glucose cotransporter
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Statistical analysis
Stroke Volume
ISSN:0028-4793, 1533-4406, 1533-4406
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Among patients with heart failure and a reduced ejection fraction, those who received the SGLT2 inhibitor empagliflozin had a significantly lower incidence of cardiovascular death or hospitalization for heart failure than those who received placebo.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2022190